-
Chiasma Plunges 14%; Feuerstein Source Says FDA Will Reject Co.'s Therapy Capsules
Thursday, April 14, 2016 - 10:05am | 258Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 14 percent Thursday morning ahead of the U.S. Food and Drug Administration's decision on Friday to approve or reject the company's therapy. Chiasma is a biopharmaceutical company that focuses on the treatment of orphan diseases. The...
-
JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval
Wednesday, May 13, 2015 - 1:55pm | 781Read More...On May 12, the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Orkambi therapy to treat cystic fibrosis. Shares of Vertex increased nearly 8 percent in pre-market trading following the announcement. The FDA advisory committee provides...
-
Market Wrap For December 31: Markets End The Year On A Positive Note
Tuesday, December 31, 2013 - 5:29pm | 1198Read More...As markets completed its final trading day of 2013, investors and traders can look back at what turned out to be a spectacular year for equities. U.S. stocks had its best year in over a decade fueled by an improving economy and the Fed's easy money policies. Commodities on the other hand have...
